Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846--a phase III study.
Schröder FH, Kurth KH, Fosså SD, Hoekstra W, Karthaus PP, Debois M, Collette L; Members of the European Organisation for the Research and Treatment of Cancer Genito-urinary Group. Schröder FH, et al. Among authors: debois m. J Urol. 2004 Sep;172(3):923-7. doi: 10.1097/01.ju.0000135742.13171.d2. J Urol. 2004. PMID: 15310999 Clinical Trial.
Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
Schröder FH, Whelan P, de Reijke TM, Kurth KH, Pavone-Macaluso M, Mattelaer J, van Velthoven RF, Debois M, Collette L; Members of the EORTC Genito-Urinary Group. Schröder FH, et al. Among authors: debois m. Eur Urol. 2004 Apr;45(4):457-64. doi: 10.1016/j.eururo.2003.11.016. Eur Urol. 2004. PMID: 15041109 Clinical Trial.
Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).
Studer UE, Collette L, Whelan P, Albrecht W, Casselman J, de Reijke T, Knönagel H, Loidl W, Isorna S, Sundaram SK, Debois M; EORTC Genitourinary Group. Studer UE, et al. Among authors: debois m. Eur Urol. 2008 May;53(5):941-9. doi: 10.1016/j.eururo.2007.12.032. Epub 2007 Dec 27. Eur Urol. 2008. PMID: 18191322 Clinical Trial.
Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group.
Oosterhof GO, Roberts JT, de Reijke TM, Engelholm SA, Horenblas S, von der Maase H, Neymark N, Debois M, Collette L. Oosterhof GO, et al. Among authors: debois m. Eur Urol. 2003 Nov;44(5):519-26. doi: 10.1016/s0302-2838(03)00364-6. Eur Urol. 2003. PMID: 14572748 Clinical Trial.
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891.
Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, Loidl W, Isorna S, Sundaram SK, Debois M, Collette L. Studer UE, et al. Among authors: debois m. J Clin Oncol. 2006 Apr 20;24(12):1868-76. doi: 10.1200/JCO.2005.04.7423. J Clin Oncol. 2006. PMID: 16622261 Clinical Trial.
Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer.
Sternberg CN, Whelan P, Hetherington J, Paluchowska B, Slee PH, Vekemans K, Van Erps P, Theodore C, Koriakine O, Oliver T, Lebwohl D, Debois M, Zurlo A, Collette L; Genitourinary Tract Group of the EORTC. Sternberg CN, et al. Among authors: debois m. Oncology. 2005;68(1):2-9. doi: 10.1159/000084201. Epub 2005 Feb 28. Oncology. 2005. PMID: 15741753 Clinical Trial.
Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.
Lutz MP, Van Cutsem E, Wagener T, Van Laethem JL, Vanhoefer U, Wils JA, Gamelin E, Koehne CH, Arnaud JP, Mitry E, Husseini F, Reichardt P, El-Serafi M, Etienne PL, Lingenfelser T, Praet M, Genicot B, Debois M, Nordlinger B, Ducreux MP; European Organisation for Research and Treatment of Cancer Gastrointestinal Group. Lutz MP, et al. Among authors: debois m. J Clin Oncol. 2005 Dec 20;23(36):9250-6. doi: 10.1200/JCO.2005.02.1980. J Clin Oncol. 2005. PMID: 16361622 Clinical Trial.
Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie.
Lutz MP, Wilke H, Wagener DJ, Vanhoefer U, Jeziorski K, Hegewisch-Becker S, Balleisen L, Joossens E, Jansen RL, Debois M, Bethe U, Praet M, Wils J, Van Cutsem E; European Organisation for Research and Treatment of Cancer Gastrointestinal Group; Arbeitsgemeinschaft Internistische Onkologie. Lutz MP, et al. Among authors: debois m. J Clin Oncol. 2007 Jun 20;25(18):2580-5. doi: 10.1200/JCO.2007.11.1666. J Clin Oncol. 2007. PMID: 17577037 Clinical Trial.
28 results